deferoxamine and 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid

deferoxamine has been researched along with 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Codd, R; Double, KL; Finkelstein, DI; Gotsbacher, MP; Telfer, TJ; Witting, PK	1

Other Studies

1 other study(ies) available for deferoxamine and 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid

Article	Year
Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease. Metallomics : integrated biometal science, 2017, 07-19, Volume: 9, Issue:7 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; Blood Proteins; Deferoxamine; Disease Models, Animal; Iron; Iron Chelating Agents; Mice; Nerve Degeneration; Neurons; Parkinson Disease; Sulfonic Acids	2017

Article

Year

Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.

Metallomics : integrated biometal science, 2017, 07-19, Volume: 9, Issue:7

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; Blood Proteins; Deferoxamine; Disease Models, Animal; Iron; Iron Chelating Agents; Mice; Nerve Degeneration; Neurons; Parkinson Disease; Sulfonic Acids

2017